Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0
Sign in

SRR598009

GTEX

729dbf0f-1de5-5af8-a1b4-994f2065b5b1

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
GTEX
cancer_type_detailed
subtype
cancer_type
GTEX
sex
Female

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • KRAS_SIGNALING_DN+0.253
  • MYOGENESIS+0.118
  • SPERMATOGENESIS+0.102
  • HEME_METABOLISM-0.024
  • PI3K_AKT_MTOR_SIGNALING-0.046
  • APICAL_JUNCTION-0.066
  • DNA_REPAIR-0.087
  • MITOTIC_SPINDLE-0.094
  • G2M_CHECKPOINT-0.122
  • WNT_BETA_CATENIN_SIGNALING-0.140

Top 10 suppressed

  • TGF_BETA_SIGNALING-0.443
  • TNFA_SIGNALING_VIA_NFKB-0.424
  • INTERFERON_ALPHA_RESPONSE-0.418
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.394
  • OXIDATIVE_PHOSPHORYLATION-0.388
  • ANGIOGENESIS-0.378
  • MTORC1_SIGNALING-0.378
  • APOPTOSIS-0.376
  • CHOLESTEROL_HOMEOSTASIS-0.368
  • INTERFERON_GAMMA_RESPONSE-0.359

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR613270
brain-umap@2
GTEX0.973
2SRR1467813
brain-umap@2
GTEX0.969
3SRR627299
brain-umap@2
GTEX0.969
4SRR1479802
brain-umap@2
GTEX0.966
5SRR1455060
brain-umap@2
GTEX0.964
6SRR615249
brain-umap@2
GTEX0.964
7SRR1436444
brain-umap@2
GTEX0.960
8SRR627453
brain-umap@2
GTEX0.958
9SRR1328960
brain-umap@2
GTEX0.957
10SRR1388504
brain-umap@2
GTEX0.957

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 3 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
KRAS_SIGNALING_DN0.253Remibrutinib— uncovered
MYOGENESIS0.118Inavolisib— uncovered
SPERMATOGENESIS0.102Inavolisib— uncovered